Optimer Pharmaceuticals Inc (OPTR.OQ)
12.61USD
1 Aug 2013
$0.10 (+0.80%)
$12.51
$12.64
$12.65
$12.60
25,292
324,197
$16.77
$8.66
About
Overall
| Beta: | 0.45 |
| Market Cap (Mil.): | $609.50 |
| Shares Outstanding (Mil.): | 48.72 |
| Dividend: | -- |
| Yield (%): | -- |
Financials
| OPTR.OQ | Industry | Sector | |
|---|---|---|---|
| P/E (TTM): | -- | 37.93 | 37.76 |
| EPS (TTM): | -1.20 | -- | -- |
| ROI: | -46.93 | 19.48 | 18.76 |
| ROE: | -47.34 | 20.17 | 19.59 |
Cubist to pay up to $1.6 billion for two antibiotics makers
- Cubist Pharmaceuticals Inc has agreed to pay up to $1.6 billion for Trius Therapeutics Inc and Optimer Pharmaceuticals Inc, expanding its heft in antibiotics at a time when the number of drug-resistant viruses are on the rise.
UPDATE 2-Cubist to pay up to $1.6 bln for two antibiotics makers
* Cubist sees the sum of both deals to be accretive in 2015
Cubist to buy Trius Therapeutics, Optimer Pharma for up to $1.62 billion
- Cubist Pharmaceuticals Inc said it would buy Trius Therapeutics Inc and Optimer Pharmaceuticals Inc for up to $1.62 billion to boost its antibiotics portfolio.
CORRECTED-Cubist to buy Trius Therapeutics, Optimer Pharma for up to $1.62 bln
(Corrects paragraphs 2 and 3 to say the per-share offers include contingency payments)
Cubist bid for Optimer before sale process began: sources
NEW YORK - Before Optimer Pharmaceuticals Inc even put itself up for sale earlier this year, Cubist Pharmaceuticals Inc offered to buy the antibiotic maker for $20 per share, or nearly $1 billion, two people familiar with the matter told Reuters on Wednesday.
Cubist bid almost $1 bln for Optimer before sale process-sources
NEW YORK, May 15 - Before Optimer Pharmaceuticals Inc even put itself up for sale earlier this year, Cubist Pharmaceuticals Inc offered to buy the antibiotic maker for $20 per share, or nearly $1 billion, two people familiar with the matter told Reuters on Wednesday.
Optimer shares rise after report names Glaxo, Cubist as potential buyers
- Shares of Optimer Pharmaceuticals Inc rose as much as 24 percent after a Bloomberg report said GlaxoSmithKline Plc and Cubist Pharmaceuticals Inc were among those interested in buying the antibiotic maker.
UPDATE 1-Optimer shares rise after report names Glaxo, Cubist as potential buyers
* Shares up 18 pct (Adds comments from an analyst, details)
Optimer Pharma exploring sale, shares jump
- Drugmaker Optimer Pharmaceuticals Inc said it was exploring a sale and replaced its chief executive as part of a review of compliance issues, sending its shares up 19 percent.
Optimer Pharma exploring sale, shares jump
- Optimer Pharmaceuticals Inc said it was exploring a possible sale of the company among a full range of alternatives and that Chairman Henry McKinnell would act as chief executive for the duration of the review process.
Competitors
| Price | Change | |
|---|---|---|
| Pfizer Inc. (PFE.N) | $29.28 | +0.05 |
| Merck & Co., Inc. (MRK.N) | $48.35 | +0.18 |
| Sanofi SA (SASY.PA) | €76.87 | -3.30 |
| Cubist Pharmaceuticals Inc (CBST.OQ) | $63.87 | +1.54 |
| Viropharma Inc (VPHM.OQ) | $32.21 | -2.11 |
| Salix Pharmaceuticals, Ltd. (SLXP.OQ) | $73.85 | -0.05 |
Earnings vs.
Estimates
Analyst Research Reports
| Report Title | Price |
|---|---|
|
Provider: ValuEngine, Inc.
|
$25.00
|
|
Provider: S&P Capital IQ Quantitative Report
|
$69.00
|
|
Provider: Thomson Reuters Stock Report
|
$25.00
|
|
Provider: Pechala's Reports
|
$15.00
|
|
Provider: Reuters Investment Profile
|
$20.00
|
NYSE and AMEX quotes delayed by at least 20 minutes. NASDAQ delayed by at least 15 minutes. For a complete list of exchanges and delays, please click here.

